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Limited data are available regarding the role of bronchoalveolar lavage (BAL) and transbron-
chial lung biopsy (TBB) as diagnostic tools in pulmonary Langerhans’ Cell Histiocytosis (LCH)
and lymphangioleiomyomatosis (LAM).
The aim of this study was to review our experience regarding the value of these two tech-
niques in the diagnosis of these cystic lung diseases.
Records of 452 patients with the presumptive diagnosis of interstitial lung disease were re-
viewed; 67 had a clinical-radiological diagnosis of either LCH (nZ 27) or LAM (nZ 40). Of 16
patients with LCH who underwent BAL, four specimens (25%) contained cells which had posi-
tive immunoreactivity for CD1a. Of three patients with negative BAL fluid who had TBB, only
one had a positive tissue diagnosis. Ten LCH patients were diagnosed by surgical lung biopsy of
which five had negative BAL fluid. The remaining 12 patients were diagnosed by clinical and
radiologic features. Standard examination of BAL fluid was of no diagnostic value in LAM.
TBB was performed in seven patients and was diagnostic in six, not resulting in complications.
All 13 patients who underwent surgical lung biopsies had a positive histopathologic diagnosis
The remaining 21 patients were diagnosed by clinical and radiologic features. We suggest that
BAL may assist in the diagnosis of LCH whereas TBB may be useful in the diagnosis of LAM, thus
avoiding the need for surgical biopsy.
ª 2012 Published by Elsevier Ltd.1 451 4950; fax: þ1 301 480 1216.
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Interstitial lung diseases constitute a heterogeneous group
of pulmonary parenchymal diseases that are defined by
radiologic, physiologic and histopathologic features.1 With
the advent of computerized tomography (CT), the radio-
logic characteristics of these conditions have been refined,
and by defining the nature of the individual lesions (e.g.,
nodules, cysts, etc) a differential diagnosis may be estab-
lished. Still, in many instances, surgical lung biopsy is
necessary to make a diagnosis. Cystic lung diseases are
a subgroup of interstitial lung diseases that are character-
ized by radiological and pathological evidence of a cystic
pattern. At advanced stages of asbestosis, cystic fibrosis,
collagen vascular diseases, usual interstitial pneumonia
(UIP), bronchiectasis, lymphangioleiomyomatosis (LAM),
Langerhans Cell Histiocytosis (LCH), Sjogrens syndrome,
and Birt Hogg Dube´ syndrome, cysts may be found
throughout the lung parenchyma.1e3 In the absence of
features of extra-pulmonary disease, diagnosis may require
clinical, radiologic and physiologic data and ultimately,
a lung biopsy.2,3 Since cystic diseases show characteristic
lesions on CT scans and may have similar clinical presen-
tation and functional impairment, a histo-
pathologicconfirmation of the diagnosis may be necessary.
However, since cystic lung diseases are relatively rare, few
data are available about the role of bronchoalveolar lavage
(BAL) and transbronchial lung biopsy (TBB) as diagnostic
tools.4 We report here our experience with BAL, TBB, and
surgical lung biopsy in 67 patients with diffuse cystic lung
diseases.
Methods
We retrospectively evaluated the records of 452 patients
referred to the Pulmonary Service of San Giuseppe Hospital
between 1997 and 2008 with a diagnosis of interstitial lung
disease. San Giuseppe Hospital is a tertiary care facility and
referral center in Milan, for undiagnosed interstitial lung
diseases. The retrospective review was approved by the San
Giuseppe Hospital Institutional Review Board (Comitato
Etico degli Ospedali di Milano e Sacra Famiglia di ERBA,
approval number 55/09), which has a Federal-Wide Assur-
ance (FWA) with the U.S. Office of Human Research
Protections, and the NHLBI Institutional Review Board
(approval number 95-H-0186). Among the 452 patients, we
found 67 patients with cystic lung disease; 27 had clinical-
radiological diagnosis of LCH and 40 had a presumptive
diagnosis of LAM. Patients with other cystic lung diseases
(e.g., cystic fibrosis, Sjogren’s syndrome, etc) were
referred to the appropriate subspecialty services. The
diagnosis of LCH was based on the presence of nodular and
cystic lesions on CT scan predominantly involving the
middle and upper lobes, history of smoking or extrap-
ulmonary involvement.5 A definite diagnosis of LAM was
based on the presence of lung cysts and angiomyolipoma,
tuberous sclerosis complex, or lymphatic involvement
(e.g., chylous effusions).3 The diagnosis of probable LAM
was made in the presence of a history of pneumothorax,
airflow obstruction and/or impairment of diffusion
capacity, and the presence of thin-walled round-shapedwell-defined cysts on the CT scan in the absence of
extrapulmonary disease.3
For each group of patients, we analyzed data for those
who underwent bronchoscopy with BAL and/or TBB, video-
assisted thoracoscopic surgery (VATS) or open lung biopsy.
Cytology and cell count and differential were performed in
all specimens. The presence of 5% or greater cells with
positive immunoreactivity for cluster of differentiation 1a
(CD1a) was considered strongly suggestive of LCH. In most
cases, cytofluorimetric studies for cluster of CD1a were also
performed. Monoclonal antibodies directed against CD1a or
the intracellular S100 protein were used to determine
immunoreactivity on lung tissue specimens. Electron
microscopy was employed to detect Birbeck granules.
When LAM was suspected, histological evaluation of speci-
mens from TBB, VATS or open lung biopsy included immu-
nohistochemical reactivity with the monoclonal antibody
HMB45. Lung biopsy tissue specimens were evaluated by
pathologists with experience in interstitial lung diseases.
Results
Langerhans cell histiocytosis
Twenty-seven patients (12 men; mean age at diagnosis
35  3 years; 22 smokers, 5 ex-smokers) received a clinical-
radiological diagnosis of LCH. Among these, seven had
multisystem disease: three had bone involvement, three
had pituitary gland disease, and one had skin involvement
(Table 1). Two subjects had respiratory failure and pulmo-
nary hypertension. The mean percent-predicted FEV1 and
DLCO were respectively, 84.4  4.1 and 67.6  4.2.
Diagnostic procedures
Sixteen patients underwent BAL. Cytology studies exam-
ining the morphology of cells stained with H&E were per-
formed in all patients. All 16 patients had
immunocytochemistry studies with CD1a. Ten of the 16 had
also had cytofluorimetric studies for cluster of CD1a. Ten
patients had positive immunocytochemistry and cyto-
fluorimetric studies for CD1a, but only four had greater
than 5% CD1a-reactive cells in their BAL fluid samples (25%).
Electron microscopy studies to search for Birbeck granules
were done in only one patient and the results were nega-
tive. No discrepancy was found between conventional
cytology and cytofluorimetry. BAL cells reactive with anti-
CD1a antibodies were found in a patient by both conven-
tional cytology and cytofluorimetric examination. In the
remaining three patients with anti-CD1a-reactive cells on
cytological evaluation of BAL fluid, cytofluorimetric studies
were not performed. TBB was performed in three patients
with negative BAL fluid analysis; a diagnosis of LCH was
established only in one case. One patient suffered a pneu-
mothorax. Ten of the 27 patients underwent surgical lung
biopsy (7 VATS and 3 open lung biopsy). All surgical lung
biopsies were diagnostic (Table 2, Fig. 1). The relationship
between CT pattern patterns and results of BAL, TBB and
surgical lung biopsy are shown in Table 3. Among the four
patients with CDa1- positive cells in BAL fluid, one had
a cystic pattern on CT scan and the others had both cysts
and nodules.
Table 1 Demographic and clinical data in 27 LCH
patients.a
Patient Sex Smoking
history
Age Extrapulmonary
manifestations
Procedure
performed
1 F ES 34 VATS
2 F S 58 FBS, BAL
3 M S 65 FBS, BAL
4 M S 36 Diabetes
insipidus
FBS, BAL
5 M ES 49
6 F S 35 Bone FBS, BAL
7 F S 46 FBS, BAL,
TBB, VATS
8 M S 24 Skin Thoracotomy,
skin biopsy
9 M S 35 FBS, BAL, VATS
10 M S 25 FBS, BAL
11 F S 24 FBS, BAL, TBB,
VATS
12 M S 19 FBS, BAL
13 F S 28 FBS, BAL
14 M S 47 FBS, BAL
15 F S 36
16 M ES 78
17 M S 23 Bone Bone biopsy
18 F S 33 VATS
19 F S 25 FBS, BAL, TBB
20 F S 23 Thoracotomy
21 F ES 51 FBS, BAL
22 M S 17 Diabetes
insipidus,
hypogonadism
FBS, BAL, VATS
23 F S 44 VATS
24 M ES 31 Bone Bone biopsy
25 F S 17 Thoracotomy
26 F S 30 Diabetes
insipidus
FBS, BAL
27 F S 14 FBS, BAL
a Abbreviations: MZ male; FZ female; SZ smoker; ESZ ex
smoker; TBB Z transbronchial lung biopsy; VATS Z video
assisted thoracoscopy; BAL Z bronchoalveolar lavage.
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Forty patients (all women; mean age at diagnosis 36  2
years, 32 non smokers, 7 ex-smokers, one smoker) received
a diagnosis of LAM. All patients showed characteristic lungTable 2 Diagnostic yield of invasive diagnostic tests in 27
patients with clinical-radiological diagnosis of Langerhans
cell histiocytosisa.
Performed Diagnostic Percent
BAL 16 4 25
TBB 3 1 33
VATS 7 7 100
Thoracotomy 3 3 100
Bone biopsy 2 2 100
a Abbreviations: see Table 1.CT scans in association with the following clinical findings:
six had TSC and angiomyolipomas; three had chylous effu-
sions and a diagnostic lymph-node biopsy; five had renal
angiomyolipomas. One patient had typical functional
impairment and a lymphangioleiomyoma. Eleven patients
had a history of recurrent or bilateral pneumothorax; nine
subjects presented with dyspnea and another patient pre-
sented with cough and hemoptysis. The mean percent-
predicted FEV1 and DLCO was respectively, 61.5  4.1 and
50.4  4.2. Other characteristics of the patients are shown
in Table 4. On the basis of clinical findings, extrapulmonary
manifestations and CT scans, 15 patients were diagnosed
with definite LAM and 25 patients with probable LAM.
Seventeen patients with probable LAM underwent addi-
tional diagnostic tests. The criteria for diagnosis of definite
or probable LAM is presented in Table 4.
Diagnostic procedures
Bronchoscopy with BAL was performed in nine of 25
patients with probable LAM of which seven underwent TBB.
In no instance were BAL fluid findings helpful for the diag-
nosis of LAM. In six cases, TBB confirmed the diagnosis
(85.7%). No complications were observed after the TBB.
Eleven patients with probable LAM underwent surgical lung
biopsy: four VATS (one patient with a non-diagnostic TBB)
and seven open lung biopsies. One VATS and one open lung
biopsy were performed after pneumothorax in two patients
with definite LAM. Four VATS biopsies confirmed the
diagnosis of LAM; all open lung biopsies were diagnostic
(Table 5, Fig. 1).Discussion
In a review of 452 patients with interstitial lung disease who
were referred to our tertiary care hospital we found 67 with
cystic lung disease, 27 with LCH and 40 with LAM. The
prevalence of these two conditions among all cases of
interstitial lung disease is high, suggesting that because San
Giuseppe Hospital is a referral center for patients with
uncommon lung diseases, our population sample may be
biased. Twenty seven patients had LCH, a smokingerelated
lung disease that is among a spectrum of disorders char-
acterized by proliferation and infiltration of organs by
Langerhans’ cells.5 Several organ systems may be involved
in LCH, including lungs, bone, skin, pituitary gland, liver,
lymph nodes, and thyroid gland.5 LCH is common in young
adults, with a peak incidence between 20 and 40 years of
age.5,6 Adult LCH may represent a subset of histiocytic
disorders, characterized by polyclonal expansion of Lang-
erhans cells in the lung, possibly induced by antigens in
cigarette smoke.7,8 Histologically, the pulmonary lesions
begin as a proliferation of Langerhans cells along the small
airways.9,10 These cells are of monocyte-macrophage
lineage and distinguished from dendritic cells by their
characteristic penta-laminar, plate-like, cytoplasmic
organelles (Birbeck granules) seen by electron microscopy.
Cells exhibit strong surface expression of the CD1a
antigen10,11 and are also reactive with anti-S-100
antibodies.11
Pathological findings vary with the stage of the disease.
In the early stages, numerous Langerhans cells accumulate
Figure 1 Illustrative diagram showing the outcome of diagnostic methods employed in 27 patients with LCH and 25 patients with
probable LAM. Abbreviations: LCHZ Langerhans’ cell histiocytosis; LAMZ lymphangioleiomyomatosis; TBBZ transbronchial lung
biopsy; VATS Z video assisted thoracoscopy; BAL Z bronchoalveolar lavage.
Role of fiberoptic bronchoscopy in cystic lung diseases 1289in areas adjacent to terminal or respiratory bronchioles.
These cells appear to invade the bronchiole, destroying the
bronchiolar wall in an eccentric fashion, and forming
nodules. The nodules contain inflammatory cells, including
Langerhans’cells, and eosinophils. These cellular nodules
progress to fibrotic nodules that often have a stellate
configuration and may lack Langerhans’ cells entirely.
Central cavitation of the nodules can sometimes be traced
to ectatic, destroyed small airways. In addition, tractionTable 3 Relationship between computed tomography
pattern and bronchoalveolar lavage, transbronchial biopsy
and video-assisted thoracoscopic surgery findings in 27
patients with clinical-radiological diagnosis of Langerhans
cell histiocytosis.
CT pattern Positive BAL Positive TBB Positive VATS
Cystic lesions 1/6 1/1 2/2
Nodules 0/2 0 1/1
Nodules and cysts 3/8 0/2 4/4
* For abbreviations see Table 1.emphysema of alveoli adjacent to the stellate scars and
peribronchiolar fibrosis are commonly observed.9 The chest
radiograph is abnormal in most cases showing micronodular
or reticulonodular and interstitial infiltration, with
a predominance of middle- and upper-lobe involve-
ment.12,13 The most common radiological findings on CT
scans are nodularity with irregularly shaped cystic changes
involving predominantly the middle and upper lobes.13
In the appropriate clinical setting, the presence of
typical findings on CT scan is often sufficient to establish
the diagnosis of LCH. A nodular and cystic pattern pre-
dominating in the upper half of the lung fields in a young
smoker makes the diagnosis almost certain and may obviate
the need for a lung biopsy.13e15 The presence CD1a-stained
cells in BAL fluid renders the diagnosis of LCH very likely.16
However, there is no gold standard for the diagnosis of LCH.
The presence of a history of smoking, bilateral pulmonary
interstitial infiltrates and nodular and cystic lesions that
spare the costophrenic angles is suggestive of LCH. To
establish a firm diagnosis, especially in those patients with
atypical roentgenographic presentation, BAL or lung biopsy
should be considered.5 In our study, using a threshold of 5%
anti-CD1a-reactive cells to increase the specificity of the
Table 4 Age, mode of presentation, extrapulmonary manifestations and procedures performed in 40 patients with
lymphangioleiomyomatosisa.
Smoking Clinical manifestations FEV1 (%) DLCO (%) Extrapulmonary
manifestations
Diagnosis Diagnostic procedures
1 NS Pneumothorax 19 22 e Probable Thoracotomy
2 NS Dyspnea 51 81 e Probable Thoracotomy
3 NS Pneumothorax 70 37 e Probable e
4 NS Pneumothorax 56 36 e Probable BAL, TBB
5 NS Pneumothorax 96 66 e Probable e
6 NS Dyspnea 96 64 Lymphangioleiomyoma Definite Abdominal biopsy
7 NS Dyspnea 49 17 Angiomyolipoma, TSC Definite e
8 ES Pneumothorax 29 37 e Probable e
9 NS Dyspnea,
pneumothorax
43 31 Angiomyolipoma Definite e
10 NS Pneumothorax e e e Probable Thoracotomy
11 ES Dyspnea 76 14 e Probable e
12 NS Dyspnea 53 e Probable e
13 NS Dyspnea 38 55 Angiomyolipoma Definite e
14 NS Pneumothorax 29 37 Angiomyolipoma Definite e
15 ES Dyspnea 62 29 e Probable BAL, TBB
16 NS Dyspnea 55 10 e Probable BAL, TBB
17 S Pneumothorax 104 85 e Probable e
18 NS Pneumothorax e e Angiomyolipoma Definite e
19 NS Pneumothorax,
dyspnea
54 61 Angiomyolipoma, TSC Definite e
20 NS Cough 78 64 Angiomyolipoma, TSC Definite e
21 NS e 85 83 Angiomyolipoma, TSC Definite e
22 NS Chylous effusion 75 60 Lymphangioleiomyomas Definite Lymph-node biopsy
23 NS Pneumothorax e e e Probable Thoracotomy
24 NS Pneumothorax 16 20 Angiomyolipoma, TSC Definite Thoracotomy
25 ES Hemoptysis, cough 70 24 e Probable Thoracotomy
26 NS Pneumothorax e e Lymphangioleiomyomas, Definite Lymph-node biopsy
angiomyolipoma, TSC
27 NS Pneumothorax 90 95 Angiomyolipoma Probable VATS
28 ES Pneumothorax 90 76 Angiomyolipoma found
after biopsy
Probable VATS
29 NS Dyspnea 71 e e Probable BAL, TBB
30 NS Pneumothorax 48 59 Angiomyolipoma, found
after biopsy
Probable Thoracotomy
31 NS Dyspnea 80 e e Probable BAL
32 NS Dyspnea 33 60 e Probable BAL, TBB, VATS
33 ES Pneumothorax 87 56 e Probable BAL, TBB
34 NS Dyspnea, chylous
effusion
24 26 Lymphangioleiomyomas Definite Lymph-node biopsy
35 NS Pneumothorax 92 65 Angiomyolipoma, found
after biopsy
Probable VATS
36 NS Pneumothorax 71 60 e Probable Thoracotomy
37 NS Chylous effusion 69 76 Lymphangioleiomyomas,
angiomyolipoma
Definite Lymph-node biopsy
38 NS Pneumothorax 95 81 Angiomyolipoma Definite VATS
39 ES Cough, dyspnea 31 26 e Probable BAL
40 NS Pneumothorax 32 13 e Probable BAL, TBB
a FEV1 and DLCO are shown as percent-predicted of the normal values. Abbreviations: NSZ non-smoker, SZ smoker, ESZ ex-smoker.
TBB Z transbronchial lung biopsy. VATS Z video-assisted thoracoscopic surgery. In the absence of extra-pulmonary LAM, a probable
diagnosis of LAM was made based on a characteristic history (recurrent pneumothorax, dyspnea, chylous effusions) in the presence of
thin-wall lung cysts on high resolution CT scans.
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Table 5 Method of diagnosis in 40 patients with LAM.
Diagnostic method Diagnostic Total Percentage
Clinical-radiologic 17 40 42.5
BAL 0 9 0
TBB 6 7 85.7
VATS 4 5 80
Open lung biopsy 8 8 100
Extra-pulmonary biopsy 5 5 100
*For abbreviations see Table 1.
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tion of LCH was obtained in four of sixteen patients (25%)
who underwent BAL. In the remaining 12 patients with
a suggestive radiological pattern, BAL fluid was not diag-
nostic, although it was useful to exclude infectious lung
diseases. Five patients with a negative BAL were found to
have LCH after lung biopsy.
Although Auerswald et al.16 and Chollet et al.19 reported
good sensitivity of immunocytochemistry against CD1a in
BAL fluid as a diagnostic test,16,19,20 our data are more in
accordance with recent evidence indicating a low sensi-
tivity of this approach.21 Examination of the BAL fluid may
be of value in patients with atypical clinical and/or radio-
logical presentation when it can be used to exclude other
interstitial lung diseases with more typical lavage findings
(e.g., sarcoidosis) and pulmonary infections, such as cavi-
tary forms of Pneumocystis Jiroveci pneumonia or myco-
bacterial infections. BAL fluid samples collected from six
patients showing cystic lesions alone on CT were diagnostic
in only one case, reflecting the absence of an active
inflammatory process. Low frequency of Langerhans cells in
BAL fluid of patients with a nodular or cystic-nodular CT
pattern may be explained by the presence of fibrotic
nodules where Langerhans cells are less abundant or
absent, as occurs in advanced disease. Three patients with
LCH had TBB and in only one was the diagnosis established,
which is consistent with the reported poor sensitivity of this
technique in LCH, ranging from 10 to 40 percent.11,22 The
patchy nature of the disease with a focal distribution of the
lesions, as well as the smaller number of active nodules in
advanced disease and the small amounts of tissue obtained
by TBB may account for the low diagnostic yield. However,
because of the small number of patients who had TBB we
are unable to draw any conclusions regarding the safety and
usefulness of TBB in the diagnosis of LCH. The value of TBB
in LCH remains to be determined.
Our data confirm that surgical lung biopsy is the best
diagnostic test in LCH patients in whom the diagnosis can
not be made by clinical-radiologic methods or BAL.
LAM is a multisystem disease characterized by prolifer-
ation of abnormal smooth muscle-like cells (LAM cells),
leading to the formation of thin-walled cysts in the lungs,
fluid-filled cystic structures (i.e., lymphangioleiomyomas)
in the axial lymphatics, and abdominal tumors (e.g. renal
angiomyolipomas).3,23 LAM occurs in a sporadic form and in
about 30% of woman with tuberous sclerosis complex
(TSC).23 LAM cells are reactive with HMB-45, a monoclonal
antibody recognizing gp100, a protein found in melanocytesand melanoma cell lines.3,23 Lung cysts are characteristi-
cally round-shaped and have thin, regular walls, ranging
from barely perceptible to several millimeter in diameter,
and typically appear scattered throughout the lung without
any lobar predominance.24e26
The gold standard for the diagnosis of LAM is a biopsy of
lung, angiomyolipomas or lymphatics.3,23 Nevertheless, not
all patients with a suspicion of LAM require tissue biopsy; in
an appropriate clinical and functional setting, the presence
of round or oval, thin-walled cysts scattered throughout the
lungs on lung CT scan, in a female makes the diagnosis of
LAM very likely. Current data suggest that a definite diag-
nosis of LAM requires manifestations other than cystic lung
disease.3 In our population, 25 of the 40 patients had
a diagnosis of probable LAM. Nine patients had a subse-
quent bronchoscopy with BAL and in 7 of those cases a TBB
was performed. The frequency of a diagnostic TBB was
high, confirming the usefulness of this test in LAM. Poletti
al.27 had already shown that LAM may be diagnosed by
transbronchial biopsy.28,29 However, in most cases, the
diagnostic features of LAM were recognized in retrospect
after review of the subsequent open lung biopsy
specimen.30,31
Our results show that TBB may be of greater usefulness
in LAM than in LCH. The more uniform distribution of
histological lesions in LAM compared to LCH possibly
accounts for this difference. The absence of complications
after TBB among LAM patients suggests the relative safety
of the procedure.
BAL is a useful diagnostic method in LCH, because of its
safety and because it may preclude the need for more
invasive tests. The poor sensitivity and risk of pneumo-
thorax do not support the use of TBB in LCH.Acknowledgments
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